Detailed introduction to the drug MEK inhibitor selumetinib

Selumetinib is an oral small molecule MEK1/2 inhibitor, developed by AstraZeneca, a world-renowned pharmaceutical company. It is currently one of the first-line targeted drugs for the treatment of certain genetic diseases and cancers. Its main mechanism of action is to selectively inhibit MEK1 and MEK2 in the mitogen-activated protein kinase pathway, thereby intervening in the abnormal activation of the RAS/MAPK signaling pathway. This pathway plays a key role in the development of various solid tumors, leukemias, neurofibromas and other diseases. Selumetinibis the first and only drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN), specifically for pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1).

1. Detailed explanation of indications

Selumetinib's current main indication is the treatment of inoperable plexiform neurofibromas in children with neurofibromatosis type 1 (NF1). NF1 is an autosomal dominant hereditary disease with an incidence rate of approximately 1/3000. The cause is that mutations in the NF1 gene lead to the loss of neurofibromin function, which further activates the RAS signaling pathway. Plexiform neurofibroma is a benign tumor originating from peripheral nerves. It often occurs in the head and neck, chest or deep parts of the trunk. Due to its irregular size and strong infiltration, this type of tumor is usually difficult to completely remove through surgery. Therefore, the emergence of selumetinib provides a new option for non-surgical treatment of this type of refractory NF1-related tumors.

2. Usage and dosage specifications

The dose of selumetinib is designed individually and is accurately calculated based on the patient's body surface area (BSA) to ensure maximum efficacy while minimizing side effects. The recommended dose is 25mg/m², taken orally twice daily, approximately 12 hours apart. This drug should be taken on an empty stomach, and no food should be eaten within 2 hours before or 1 hour after each dose to ensure good bioavailability and stable blood concentration. For children with different body surface areas, the dosage is as follows:

BSA 0.55-0.69m²: 20mg in the morning and 10mg in the evening; BSA 0.70-0.89m²: 20mg each twice daily; BSA 0.90-1.09m²: 25mg each twice daily; BSA 1.10-1.29m²: 30mg each twice daily; BSA 1.30-1.49m²: 35mg each twice daily; BSA 1.50-1.69m²: 40mg twice daily; BSA 1.70-1.89m²: 45mg twice daily; BSA≥1.90m²: 50mg twice daily.

It is worth noting that there is no recommended dose for patients whose body surface area is less than0.55m², and treatment must be carefully formulated by professional doctors after evaluation by authoritative medical institutions.

3. Side Effects and Monitoring Key Points

Common adverse reactions of selumetinib include rash, diarrhea, fatigue, nausea, stomatitis and blurred vision. Abnormal liver function or changes in cardiac function may also occur during long-term use, so it is recommended to regularly monitor liver enzyme levels, left heart ejection fraction (LVEF) and eye examinations. For patients who experience severe toxicity, appropriate strategies for dose reduction, medication interruption, or permanent discontinuation need to be considered.

4. Clinical application and market situation in China

Currently, selumetinib has been approved by the National Food and Drug Administration (NMPA) in China, becoming the first targeted drug for NF1-related PN. The drug has been included in the national medical insurance catalog, greatly improving its accessibility to domestic patients. It is worth mentioning that generic drugs have also begun to be launched in Southeast Asia. For example, the generic version of Lucius Pharmaceuticals in Laos has the same ingredients as the original drug and is more affordable, further expanding the influence of the drug in the global rare disease treatment market.

Reference materials:https://www.koselugo.com